{"nctId":"NCT02322593","briefTitle":"Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer","startDateStruct":{"date":"2014-12","type":"ACTUAL"},"conditions":["Gastric Cancer"],"count":711,"armGroups":[{"label":"TAS-118/Oxaliplatin","type":"EXPERIMENTAL","interventionNames":["Drug: TAS-118 plus Oxaliplatin"]},{"label":"S-1/Cisplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: S-1 plus Cisplatin"]}],"interventions":[{"name":"TAS-118 plus Oxaliplatin","otherNames":[]},{"name":"S-1 plus Cisplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Patients who are diagnosed as gastric cancer.\n* No prior treatment for gastric cancer.\n* Negative or unknown for HER2 testing.\n* ECOG performance status of 0 or 1.\n\nKey Exclusion Criteria:\n\n* Unmanageable diarrhea.\n* Current peripheral sensory neuropathy or paresthesia.\n* Pregnant or lactating female.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"The primary endpoint was OS, which was defined as the time from the date of randomization to the date of death from any cause. Surviving patients were censored at the cutoff date or last contact date if lost to follow-up, or upon withdrawal of consent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"PFS was defined as the time from the date of randomization to the date of disease progression (assessed by each investigator) or death from any cause, whichever came first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure","description":"TTF was defined as the time from the date of randomization to the date of the last administration of the study drug. Patients on study treatment were censored at the date of the last administration or the cutoff date, whichever came earlier.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate","description":"ORR was defined as the proportion of patients with the best unconfirmed overall response of complete response (CR) or partial response (PR) in patients with measurable lesions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate","description":"DCR was defined as the proportion of patients with CR, PR, or stable disease in patients with measurable lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":155,"n":352},"commonTop":["Decreased appetite","Nausea","Diarrhoea","Peripheral sensory neuropathy","Stomatitis"]}}}